RPL14B Antibody

What is RPL14 and why is it important in research?

RPL14 (Ribosomal Protein L14) is a component of the large ribosomal subunit that belongs to the L14E family of ribosomal proteins. This protein plays a critical role in ribosome assembly and stability, making it an important target for studies focused on protein synthesis, cellular growth, and various disease mechanisms. RPL14 has a calculated molecular weight of 23 kDa, though it typically appears at 25-30 kDa in Western blot applications due to post-translational modifications . The protein is encoded by the RPL14 gene (ID: 9045) and has been implicated in various cellular processes beyond its structural role in ribosomes, including potential involvement in cell proliferation pathways that are relevant to cancer research .

What applications are RPL14 antibodies typically used for?

RPL14 antibodies have been validated for multiple research applications:

These applications enable researchers to investigate RPL14 expression, localization, and interactions across different experimental contexts and model systems .

Which species do commercial RPL14 antibodies react with?

Commercial RPL14 antibodies have demonstrated reactivity with samples from multiple species:

When selecting an antibody for cross-species applications, verify the sequence homology between your species of interest and the immunogen used to generate the antibody. This is particularly important for evolutionary studies or when working with non-standard model organisms .

What are the recommended storage conditions for RPL14 antibodies?

For optimal stability and performance, RPL14 antibodies should be stored according to the following recommendations:

• Temperature: Store at -20°C for long-term preservation .

• Buffer composition: Most commercial preparations are supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

• Aliquoting: While some products specifically state that aliquoting is unnecessary for -20°C storage , it's generally good practice to prepare small aliquots to avoid repeated freeze-thaw cycles, which can degrade antibody quality over time .

• Stability: When stored properly, these antibodies are typically stable for one year after shipment .

Always check the manufacturer's specific recommendations, as formulations may vary between suppliers .

How should experimental conditions be optimized when using RPL14 antibodies for Western blotting?

Optimizing Western blot protocols for RPL14 detection requires attention to several technical parameters:

• Sample preparation: Since RPL14 is a ribosomal protein, cellular fractionation may help enrich for ribosomal components. Include protease inhibitors to prevent degradation and phosphatase inhibitors if studying phosphorylated forms of RPL14 (Y14 and T43 are known phosphorylation sites) .

• Antibody dilution optimization: The recommended dilution ranges vary significantly (1:500-1:50000) , requiring empirical determination for each experimental system:

  • Begin with a mid-range dilution (1:5000)

  • Test a dilution series if background is high or signal is weak

  • For Proteintech antibody (14991-1-AP), very high dilutions (up to 1:50000) may be suitable for abundant samples

• Detection systems: Consider using highly sensitive chemiluminescent substrates, particularly when working with tissue samples where RPL14 expression may be lower than in transformed cell lines.

• Expected molecular weight considerations: While the calculated molecular weight is 23 kDa, RPL14 typically appears at 25-30 kDa in SDS-PAGE . This discrepancy should be anticipated when interpreting results and may vary between different sample types.

• Positive controls: HEK-293, HepG2, HeLa, and MCF-7 cell lysates have been validated as positive controls for RPL14 detection .

What are the critical considerations for immunofluorescence applications with RPL14 antibodies?

When conducting immunofluorescence studies with RPL14 antibodies, researchers should consider:

• Fixation method: Paraformaldehyde (4%) fixation is generally suitable, but comparison with methanol fixation may be warranted as it can better preserve the structural integrity of nucleolar components.

• Permeabilization optimization: Since RPL14 is primarily localized to the nucleolus and cytoplasm, adequate permeabilization is essential. Triton X-100 (0.1-0.5%) is typically effective, but gentler detergents like saponin may be preferable if studying RPL14 in the context of intact ribosomal structures.

• Blocking parameters: Extended blocking times (1-2 hours) with 5% BSA or normal serum matching the secondary antibody host species helps minimize background from non-specific binding.

• Antibody dilution: Start with the manufacturer's recommended range (1:20-1:200) , optimizing based on signal-to-noise ratio.

• Co-localization studies: Consider counterstaining with nucleolar markers (e.g., fibrillarin or nucleolin) to confirm the expected subcellular localization of RPL14.

• Validated cell lines: HepG2 cells have been specifically validated for IF/ICC applications with RPL14 antibodies .

How can researchers troubleshoot non-specific binding or high background issues with RPL14 antibodies?

Non-specific binding and high background are common challenges when working with ribosomal protein antibodies like RPL14. Systematic troubleshooting approaches include:

• Antibody validation with appropriate controls:

  • Include a negative control with secondary antibody only

  • When possible, include RPL14 knockdown/knockout samples

  • Consider peptide competition assays with the immunizing peptide/protein

• Optimization of blocking conditions:

  • Test different blocking agents (BSA, milk, normal serum)

  • Extend blocking time from 1 hour to overnight at 4°C

  • Include 0.1-0.3% Triton X-100 in the blocking solution for improved penetration

• Wash optimization:

  • Increase the number and duration of wash steps

  • Consider adding low concentrations of detergent (0.05-0.1% Tween-20) to wash buffers

  • Use TBS instead of PBS if phospho-specific detection is important

• Antibody dilution and incubation parameters:

  • Further dilute primary antibody if background persists

  • Extend primary antibody incubation to overnight at 4°C

  • Pre-absorb antibody with cell/tissue lysate from a different species

• Detection system considerations:

  • For fluorescence applications, ensure proper filter sets to avoid autofluorescence

  • For chromogenic detection, optimize substrate development times

• Sample-specific adjustments:

  • For IHC applications, optimize antigen retrieval methods (both TE buffer pH 9.0 and citrate buffer pH 6.0 have been validated for RPL14)

  • For heavily fixed samples, consider extended antigen retrieval times

How do post-translational modifications affect RPL14 detection and what methods can address this?

RPL14 undergoes several post-translational modifications (PTMs) that can impact antibody detection and protein function:

To address these challenges:

• Phosphorylation-specific detection:

  • Include phosphatase inhibitors in lysis buffers

  • Consider phosphorylation-specific antibodies if studying phospho-Y14 or phospho-T43

  • Lambda phosphatase treatment of parallel samples can confirm phosphorylation-dependent mobility shifts

• Ubiquitination analysis:

  • Include deubiquitinating enzyme inhibitors in lysis buffers

  • Use immunoprecipitation followed by ubiquitin-specific Western blotting

  • Consider proteasome inhibitors (MG132) for treating cells before analysis

• Acetylation studies:

  • Include deacetylase inhibitors in lysis buffers

  • Two-dimensional gel electrophoresis can resolve differently modified forms

• Analysis of multiple PTMs:

  • Mass spectrometry following immunoprecipitation can identify specific PTM patterns

  • Comparison of band patterns between different tissues/conditions may reveal functional significance of modifications

Understanding these modifications is critical for interpreting experimental results, as PTMs may vary under different physiological conditions or disease states .

What are the key considerations when designing RPL14 knockdown validation experiments?

When validating RPL14 antibody specificity or studying RPL14 function through knockdown experiments:

• Selection of appropriate knockdown method:

  • siRNA: Effective for transient knockdown; may require optimization of transfection conditions for ribosomal proteins

  • shRNA: Better for long-term studies but may be challenging due to potential cellular growth defects

  • CRISPR/Cas9: Consider using inducible systems as complete knockout may be lethal

• Controls for antibody validation:

  • Include non-targeting siRNA/shRNA controls

  • Consider rescue experiments with an siRNA-resistant RPL14 construct

  • Use multiple siRNAs targeting different regions of RPL14 mRNA

• Timing considerations:

  • Assess knockdown efficiency at multiple time points (48-96 hours)

  • Monitor cellular viability as RPL14 depletion may affect ribosome assembly and protein synthesis

• Detection methods:

  • Confirm knockdown at both mRNA level (qRT-PCR) and protein level (Western blot)

  • The high dilution capacity of RPL14 antibodies (1:5000-1:50000) allows for detection of varying expression levels

• Functional readouts:

  • Include assays for ribosome assembly and/or protein synthesis rates

  • Consider polysome profiling to assess impact on translation

How can researchers distinguish between RPL14 and related ribosomal proteins in complex samples?

Distinguishing RPL14 from other ribosomal proteins presents challenges due to structural similarities and potential cross-reactivity:

• Antibody selection for specificity:

  • Review the immunogen sequence used to generate the antibody

  • Compare with sequences of other ribosomal proteins, particularly those of similar molecular weight

  • When possible, select antibodies raised against unique regions of RPL14

• Experimental approaches to confirm specificity:

  • Immunoprecipitation followed by mass spectrometry

  • Multiple antibody validation using antibodies targeting different epitopes

  • Expression of tagged RPL14 as a size-differentiated positive control

• Optimization of SDS-PAGE conditions:

  • Use gradient gels (10-20%) for better resolution of similarly sized ribosomal proteins

  • Extended running times can improve separation in the relevant molecular weight range

  • Consider using Phos-tag™ acrylamide gels if focusing on phosphorylated forms

• Two-dimensional electrophoresis:

  • Separation based on both isoelectric point and molecular weight can resolve RPL14 from similarly sized proteins

  • May reveal different post-translationally modified forms of RPL14

• Sequential immunoblotting:

  • Strip and reprobe membranes with antibodies against potential cross-reactive proteins

  • Compare signal patterns and intensities

What cellular stress conditions might affect RPL14 expression and how should this impact experimental design?

Ribosomal proteins including RPL14 can be affected by various cellular stresses, which researchers should consider when designing experiments:

• Nutrient deprivation responses:

  • Amino acid starvation may trigger complex changes in ribosomal protein expression

  • Include appropriate time course analysis to capture dynamic changes

  • Monitor mTOR signaling pathway activation as a parallel readout

• Cell cycle dependencies:

  • Consider synchronizing cells when comparing RPL14 expression between conditions

  • Include cell cycle phase markers in analysis (e.g., cyclin levels by Western blot)

• Transcriptional and translational inhibitors:

  • Actinomycin D (transcription inhibitor) or cycloheximide (translation inhibitor) treatments can help dissect regulatory mechanisms

  • These inhibitors may reveal different pools of RPL14 (free vs. ribosome-incorporated)

• Oxidative stress considerations:

  • RPL14 contains sites susceptible to oxidative modifications (e.g., C42 S-nitrosylation)

  • Include reducing agents in lysis buffers when analyzing oxidation-sensitive epitopes

  • Consider parallel detection of oxidative stress markers

• Experimental design recommendations:

  • Include time course analyses rather than single time points

  • Consider cellular fractionation to distinguish changes in RPL14 subcellular distribution

  • Pair protein-level analyses with mRNA quantification to determine regulatory level

Understanding stress-dependent changes in RPL14 expression or modification can provide insights into regulatory mechanisms and potentially identify novel functions beyond its structural role in ribosomes.

How can RPL14 antibodies be effectively used in co-immunoprecipitation studies to identify interaction partners?

Co-immunoprecipitation (Co-IP) with RPL14 antibodies requires careful optimization to preserve physiologically relevant interactions:

• Lysis conditions optimization:

  • Use mild non-ionic detergents (0.5-1% NP-40 or 0.5% Triton X-100)

  • Include protease and phosphatase inhibitors to maintain interaction integrity

  • Consider crosslinking approaches for transient or weak interactions

• RPL14 antibody selection for Co-IP:

  • Validate antibody efficacy for IP applications before Co-IP experiments

  • Proteintech antibody (14991-1-AP) has been specifically validated for IP in mouse liver tissue

  • Consider using multiple antibodies recognizing different epitopes to confirm results

• Controls and validation approaches:

  • Include IgG control from the same host species

  • Perform reverse Co-IP when antibodies to potential interacting partners are available

  • Include RNase treatment controls to distinguish RNA-dependent from direct protein-protein interactions

• Detection strategies:

  • Western blotting for known/suspected interacting partners

  • Mass spectrometry for unbiased identification of the interaction network

  • Consider proximity labeling approaches (BioID or APEX) as complementary methods

• Data interpretation considerations:

  • Distinguish between direct interactions and those mediated by ribosome structure

  • Use nuclease treatments to determine RNA-dependence of interactions

  • Consider subcellular fractionation to identify compartment-specific interactions

These approaches can reveal how RPL14 functions within and potentially outside the context of mature ribosomes.

What are the critical considerations when using RPL14 antibodies in chromatin immunoprecipitation (ChIP) or RNA immunoprecipitation (RIP) studies?

While ribosomal proteins are primarily involved in translation, emerging evidence suggests potential roles in transcriptional regulation and RNA processing. When using RPL14 antibodies for ChIP or RIP:

• ChIP optimization for RPL14:

  • Crosslinking conditions: Test both short (10 min) and extended (20-30 min) formaldehyde crosslinking

  • Sonication parameters: Optimize chromatin fragmentation to 200-500 bp

  • Include appropriate controls (IgG, input, positive control regions)

  • Consider sequential ChIP (re-ChIP) to identify co-occupancy with transcription factors

• RIP protocol considerations:

  • Crosslinking: UV crosslinking may be preferable for direct protein-RNA interactions

  • RNase inhibition: Include multiple RNase inhibitors in all buffers

  • Controls: Include samples treated with RNase A before immunoprecipitation

  • Validation: Confirm enrichment of known ribosomal RNAs as positive controls

• Antibody selection criteria:

  • Epitope accessibility: Consider whether the antibody epitope might be masked in chromatin or RNP complexes

  • Specificity validation: Perform Western blots on nuclear extracts to confirm specificity

  • Functional blocking: Test whether the antibody might disrupt important interactions

• Data analysis considerations:

  • For ChIP-seq: Compare RPL14 binding sites with known transcription factors

  • For RIP-seq: Distinguish between ribosomal RNAs and potential regulatory RNA interactions

  • Pathway analysis: Examine whether RPL14-associated genes/RNAs share common functions

These specialized applications may reveal novel functions of RPL14 beyond its canonical role in ribosome structure.

How can multiplexed imaging approaches be optimized when using RPL14 antibodies alongside other ribosomal protein markers?

Multiplexed imaging can provide insights into ribosome heterogeneity and RPL14's relationship with other ribosomal components:

• Antibody compatibility assessment:

  • Host species considerations: Select primary antibodies from different host species when possible

  • Isotype differences: Use isotype-specific secondary antibodies when primaries are from the same host

  • Sequential detection: Consider sequential staining with complete elution between rounds for incompatible antibodies

• Fluorophore selection strategies:

  • Spectral separation: Choose fluorophores with minimal spectral overlap

  • Signal intensity balancing: Match fluorophore brightness with expected target abundance

  • Photobleaching minimization: Select stable fluorophores for targets requiring extended imaging

• Advanced imaging approaches:

  • Super-resolution techniques (STORM, PALM, SIM) for studying ribosome assembly sites

  • FRET-based approaches to detect proximity between RPL14 and other ribosomal proteins

  • Live-cell imaging using genetically encoded tags as complementary approaches

• Controls for multiplexed imaging:

  • Single-stained controls for spectral unmixing

  • Secondary-only controls for each detection channel

  • Peptide competition controls to confirm specificity in the multiplexed context

• Data analysis considerations:

  • Co-localization algorithms beyond visual assessment

  • 3D reconstruction for spatial relationship analysis

  • Quantitative analysis of stoichiometry at different cellular locations

These approaches can provide insights into potential ribosome heterogeneity and reveal whether RPL14 might be present in specialized ribosome subpopulations.

How can RPL14 antibodies be used to investigate ribosomal dysfunction in disease models?

Ribosomal proteins, including RPL14, have been implicated in various diseases, particularly cancer and ribosomopathies. When using RPL14 antibodies in disease research:

• Cancer research applications:

  • Compare RPL14 expression across tumor grades/stages

  • Investigate correlation with proliferation markers

  • Examine nuclear vs. cytoplasmic localization in different cancer types

  • The antibody has been validated for human colon cancer tissue in IHC applications

• Neurodegenerative disease models:

  • Assess RPL14 levels in models of protein misfolding diseases

  • Investigate co-localization with stress granules or processing bodies

  • Examine relationship to translational efficiency in affected neurons

• Stress response characterization:

  • Monitor RPL14 modification status under different stress conditions

  • Investigate potential extraribosomal functions during cellular stress

  • Examine correlation with integrated stress response markers

• Tissue-specific considerations:

  • Optimize antigen retrieval for different tissue types

  • For liver tissue, both mouse and rat samples have been specifically validated

  • Consider tissue-specific expression levels when optimizing antibody dilutions

• Developmental and stem cell applications:

  • Investigate RPL14 expression during differentiation processes

  • Examine potential regulatory roles in stem cell maintenance

  • Compare with other ribosomal proteins to identify differential regulation

These applications can help elucidate how ribosomal protein dysfunction contributes to disease pathophysiology and potentially identify novel therapeutic targets.

What validation approaches are essential when using RPL14 antibodies in patient-derived samples?

Working with clinical specimens requires additional validation steps to ensure reliable results:

• Fixation-dependent optimizations:

  • For FFPE samples: Extended antigen retrieval may be necessary

  • Compare different retrieval methods (TE buffer pH 9.0 and citrate buffer pH 6.0 have both been recommended)

  • Freshly fixed versus archived samples may require different protocols

• Patient sample heterogeneity considerations:

  • Include appropriate normal tissue controls from similar sources

  • Consider age, gender, and treatment status as potential variables

  • Batch processing of samples to minimize technical variability

• Specificity confirmation approaches:

  • Peptide competition assays to confirm specificity in human tissues

  • Multiple antibody validation using antibodies to different epitopes

  • Correlation with mRNA expression when possible

• Quantification methods:

  • Consistent scoring systems for IHC (H-score, Allred, etc.)

  • Digital pathology approaches for standardized analysis

  • Consider multiplex IHC to provide cellular context

• Technical validation:

  • Inter- and intra-observer reproducibility assessment

  • Technical replicate analysis to ensure consistency

  • Correlation with alternative detection methods when available

These rigorous validation approaches help ensure that findings in patient samples are robust and reproducible, particularly important for potential diagnostic or prognostic applications.